Coamplification of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Genes in Methotrexate-Resistant Human Leukemia Cell Lines
Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 12, Number 1, 2001 , pp. 11-15(5)
Publisher: Cognizant Communication Corporation
Abstract:Methotrexate (MTX)-resistant K562 human myelocytic leukemia sublines with 20- and 200-fold amplified dihydrofolate reductase (DHFR) genes localized to homogeneously staining regions (HSRs) on the long arms of chromosomes 5, 6, and 19 were used to examine whether other genes mapping close to the DHFR genes were coamplified. The gene for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, located on chromosome 5q13.3-14, was coamplified 4–14-fold, corresponding to the levels of resistance exhibited by these cells. Similar observations were made with a MTX-resistant subline of the promyelocytic leukemia cell line, HL-60R, with 200 gene copies of DHFR. These observations indicate a tight linkage of DHFR and HMG-CoA genes on chromosome 5q.
Document Type: Research Article
Affiliations: 1: *Department of Medicine, Yale University School of Medicine, New Haven, CT 06510 2: †Center for Agricultural Biotechnology, University of Maryland Biotechnology Institute, College Park, MD 20742-4450
Publication date: 2001-01-01
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.